2025: Cure Parkinson's research highlights from the last year and insights for the year ahead
2024 was another busy year for the research team at Cure Parkinson’s; from the results publication of the phase 2 clinical trial of lixisenatide to the funding of new pre-clinical projects, Cure Parkinson’s has not stopped in its mission to slow, stop or reverse Parkinson’s....
Learn more
Similarities between Alzheimer’s and Parkinson’s
Recently, two research groups independently published journal articles suggesting that a genetic variation associated with Alzheimer’s might also have an important influence in Parkinson’s and related conditions. The scientists found that a protein called Apolipoprotein E (or ApoE) can affect the severity of the toxic accumulation…
New developments in diabetes drugs for Parkinson’s
At the forefront of treatments for diabetes is a class of drug called glucagon-like peptide 1 receptor (or GLP-1R) agonists. There is also now considerable laboratory research that suggests GLP-1R diabetes drugs could potentially be used in the treatment of Parkinson’s. An agonist is a drug that…
The Bydureon phase 3 trial: supplementary substudies
Cure Parkinson’s and Van Andel Institute (VAI) are delighted to be supporting two sub-studies within the important Bydureon phase 3 trial (Exenatide-PD 3)
Cure Parkinson’s – 15 Years
2020 is a milestone year for Cure Parkinson’s. It marks our 15th year of investing in pioneering Parkinson’s research and a chance to reflect on the advances we have achieved within the Parkinson’s arena. We are not celebrating this 15th anniversary as such, but rather…
IPDGC 2019: London
The International Parkinson Disease Genomics Consortium (IPDGC) held their annual meeting in London in December. Over 150 researchers working on the genetics of Parkinson’s attended the two-day event which was sponsored by Cure Parkinson’s. The IPDGC is a group of highly collaborative scientists, who are…